Paper21531979
Autoimmunity associated with immunotherapy of cancer.
Amos SM and 6 others. Blood, 2011. Cited by 140 papers, by iCite.
Cite this record
ConductScience Library. Autoimmunity associated with immunotherapy of cancer. Papers, record 21531979. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21531979
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Autoimmunity | Major topic |
| Immunotherapy | Major topic |
| Neoplasms | Major topic |
| Humans |
Source PubMed
Cited by82
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 140 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41383611 | TRIM21 regulation of IRF-mediated type I interferon signaling in systemic autoimmune diseases. | Front Immunol | 2025 | https://conductscience.org/library/papers/41383611 | PubMed |
| 41041059 | Dissecting Tertiary Lymphoid Structures in Cancer: Maturation, Localization and Density. | Theranostics | 2025 | https://conductscience.org/library/papers/41041059 | PubMed |
| 40734391 | Severe oral and cutaneous immune-related adverse events induced by PD-1 inhibitors and antibody-drug conjugates: Case reports and management strategies. | Sci Prog | 2025 | https://conductscience.org/library/papers/40734391 | PubMed |
| 40141809 | Anti-Cancer Strategies Using Anaerobic Spore-Forming Bacteria Clostridium: Advances and Synergistic Approaches. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40141809 | PubMed |
| 40093652 | Immune-based strategies for the treatment of biofilm infections. | Biofilm | 2025 | https://conductscience.org/library/papers/40093652 | PubMed |
| 38414708 | Dupilumab-Related Diabetes Mellitus With Reversal of Symptoms in a Non-genetically Predisposed Patient. | Cureus | 2024 | https://conductscience.org/library/papers/38414708 | PubMed |
| 38260723 | Transplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines. | Oncol Rev | 2023 | https://conductscience.org/library/papers/38260723 | PubMed |
| 37962824 | Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities. | Curr Treat Options Oncol | 2023 | https://conductscience.org/library/papers/37962824 | PubMed |
| 37584709 | PTPN3 inhibition contributes to the activation of the dendritic cell function to be a promising new immunotherapy target. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/37584709 | PubMed |
| 37511873 | Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer. | Life (Basel) | 2023 | https://conductscience.org/library/papers/37511873 | PubMed |
| 37345057 | Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345057 | PubMed |
| 36678712 | Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36678712 | PubMed |
| 35920952 | Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases. | Curr Rheumatol Rep | 2022 | https://conductscience.org/library/papers/35920952 | PubMed |
| 35761353 | Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1. | BMC Chem | 2022 | https://conductscience.org/library/papers/35761353 | PubMed |
| 35686131 | Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens. | Front Immunol | 2022 | https://conductscience.org/library/papers/35686131 | PubMed |
| 35459932 | Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse. | Heredity (Edinb) | 2022 | https://conductscience.org/library/papers/35459932 | PubMed |
| 35335994 | LncRNA: A Potential Target for Host-Directed Therapy of Candida Infection. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35335994 | PubMed |
| 34734110 | Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress. | Adv Ther (Weinh) | 2021 | https://conductscience.org/library/papers/34734110 | PubMed |
| 34642183 | Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages. | Cancer Res | 2021 | https://conductscience.org/library/papers/34642183 | PubMed |
| 34532602 | Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment. | Glob Health Med | 2021 | https://conductscience.org/library/papers/34532602 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21531979
GET https://conductscience.org/api/papers/v1/21531979/cited_by?page=2